[1]李依依,韩颖,田秀标,等.天津市糖尿病高危人群血脂异常患病率 及相关危险因素分析[J].国际内分泌代谢杂志,2016,36(03):166.[doi:10.3760/cma.j.issn.1673-4157.2016.03.06]
　Li Yiyi*,Han Ying,Tian Xiubiao,et al.The prevalence and risk factors of dyslipidemia in high-risk population of diabetes in Tianjin[J].International Journal of Endocrinology and Metabolism,2016,36(03):166.[doi:10.3760/cma.j.issn.1673-4157.2016.03.06]
点击复制

天津市糖尿病高危人群血脂异常患病率 及相关危险因素分析()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年03期
页码:
166
栏目:
短篇论著
出版日期:
2016-05-20

文章信息/Info

Title:
The prevalence and risk factors of dyslipidemia in high-risk population of diabetes in Tianjin
作者:
李依依; 韩颖; 田秀标; 刘艳; 于珮
300070 天津医科大学代谢病医院糖尿病肾病透析科,卫生部激素与发育重点实验室(李依依,于珮); 300280 天津海滨人民医院内分泌科(韩颖,田秀标,刘艳)
Author(s):
Li Yiyi*;  Han Ying;  Tian Xiubiao;  Liu Yan;  Yu Pei.
*Department of Diabetic Nephrology Dialysis, Key Laboratory of Hormones and Development, Ministry of Health, The Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China
关键词:
糖尿病高危人群;  糖尿病;  血脂异常;  危险因素
Keywords:
High-risk population of diabetes;  Diabetes mellitus;  Dyslipidemia;  Risk factors
DOI:
10.3760/cma.j.issn.1673-4157.2016.03.06
摘要:
目的 探讨天津市糖尿病高危人群血脂异常患病率及相关危险因素。方法 在天津地区采用随机数字法选取1 364名无明确糖尿病病史的健康查体者作为筛查对象。采用芬兰糖尿病风险积分表(FINDRSC)筛查糖尿病高危人群,将纳入的445名糖尿病高危人群按是否合并血脂异常分为血脂异常组(n=316)和血脂正常组(n=129)。比较两组间一般情况、生化指标及胰岛素抵抗和胰岛β细胞功能状态,测定纤溶酶原激活物抑制因子-1(PAI-1)及颈动脉内膜-中层厚度(IMT),并分析糖尿病高危人群血脂异常患病率及相关危险因素。结果 天津地区糖尿病高危人群血脂异常总患病率为71.01%(316/445),高甘油三酯血症、高胆固醇血症、高低密度脂蛋白-胆固醇血症、低高密度脂蛋白-胆固醇血症的患病率分别为47.86%(213/445)、21.57%(96/445)、19.55%(87/445)、39.33%(175/445)。其中单纯型血脂异常患者占28.76%(128/445),混合型血脂异常患者占42.25%(188/445)。血脂异常的程度与吸烟、FINDRSC评分、腰围、体重指数、收缩压、谷草转氨酶、谷丙转氨酶、血尿酸、C反应蛋白、同型半胱氨酸(Hcy)、IMT、PAI-1及稳态模型评估-胰岛素抵抗指数(HOMA2-IR)呈正相关(r=0.145～0.786,P均<0.05),与规律运动及稳态模型评估-胰岛β细胞功能状态(HOMA2-%β)呈负相关(r=-0.344,-0.424,P均<0.05)。二分类Logistic回归分析提示,血脂异常的发生与体重指数(OR=1.754,95%CI:1.399～2.199),腰围(OR=1.091,95%CI:1.004～1.186), 收缩压(OR=1.201,95%CI:1.131～1.276), 血尿酸(OR=1.008,95%CI:1.002～1.014), PAI-1(OR=1.233,95%CI:1.150～1.323), HOMA2-IR(OR=4.094,95%CI:1.352～12.397)及HOMA2-%β(OR=0.921, 95%CI:0.888～0.954)独立相关(P均<0.05)。结论 血脂异常尤其混合型血脂异常在天津地区糖尿病高危人群中的患病率很高; 高体重指数、高腰围、高收缩压、高尿酸、高PAI-1、高胰岛素抵抗程度及胰岛β细胞功能减低是血脂异常的独立危险因素。
Abstract:
Objective To explore the prevalence and risk factors of dyslipidemia in high-risk population of diabetes in Tianjin. Methods A total of 1 364 healthy individuals without diabetes history in Tianjin were organized to complete the diabetes risk score(FINDRSC)according to the random number method and then 445 subjects were enrolled in this study and were divided into two groups based on the levels of blood lipids: dyslipidemia group(n=316)and normal blood lipids group(n=129). The general conditions,biochemical indicators, insulin resistance and β-cell function were compared between the two groups. The level of plasminogen activator inhibitor-1 and intima-media thickness were detected. The prevalence and risk factors of dyslipidemia in high-risk polulation of diabetes were evaluated. Results The prevalence of dyslipidemia was 71.01%(316/445)in high-risk population of diabetes in Tianjin. The percentage of subjects with hypertriglyceridemia, hypercholesterolemia, high level of blood low-density lipoprotein(LDL)cholesterol and low level of blood high-density lipoprotein(HDL)cholesterol was 47.86%(213/445), 21.57%(96/445), 19.55%(87/445)and 39.33%(175/445), respectively. The prevalence of simple and mixed dyslipidemia was 28.76%(128/445)and 42.25%(188/445), respectively. The severity of dyslipidemia was positively related to smoking, FINDRSC score, waist circumference, body mass index, systolic blood pressure, aspartate aminotransferase, alanine aminotransferase, uric acid, C-reactive protein, homocysteine, intima-media thickness, plasminogen activator inhibitor-1 and homeostasis model assessment 2-insulin resistance(HOMA2-IR)index(r=0.145-0.786, all P<0.05), while negatively related to regular exercise and homeostasis model assessment 2-%β(HOMA2-%β)index(r=-0.344, -0.424,all P<0.05).The binary Logistic regression analysis showed that body mass index(OR=1.754,95%CI:1.399-2.199), waist circumference(OR=1.091, 95%CI:1.004-1.186), systolic blood pressure(OR=1.201,95%CI:1.131-1.276), uric acid(OR=1.008, 95%CI:1.002-1.014), plasminogen activator inhibitor-1(OR=1.233, 95%CI:1.150-1.323),HOMA2-IR(OR=4.094, 95%CI:1.352-12.397)and HOMA2-%β(OR=0.921, 95%CI:0.888-0.954)were independent risk factors of dyslipidemia(all P<0.05). Conclusion The prevalence of dyslipidemia, especially the mixed dyslipidemia, is quite high in high-risk population of diabetes in Tianjin.The high levels of body mass index, waist circumference, systolic blood pressure, uric acid, plasminogen activator inhibitor-1, HOMA2-IR index and low HOMA2-%β index are independent risk factors of dyslipidemia.

参考文献/References:

[1] Piya-Anant M,Therasakvichya S,Leelaphatanadit C,et al. Integrated health research program for the Thai elderly: prevalence of genital prolapse and effectiveness of pelvic floor exercise to prevent worsening of genital prolapse in elderly women[J].J Med Assoc Thai,2003,86(6):509-515.
[2] Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research[J].World J Diabetes,2015,6(13):1246-1258. DOI: 10.4239/wjd.v6.i13.1246.
[3] Lindstr m J,Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk[J].Diabetes Care,2003,26(3):725-731.
[4] American Diabetes Association. Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2014,37(Suppl 1):S81-S90. DOI: 10.2337/dc14-S081.
[5] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel Ⅲ)[J]. JAMA,2001,285(19):2486-2497.
[6] 中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419.
[7] 中华医学会内分泌学分会肥胖学组.中国成年肥胖症防治专家共识[J].中华内分泌代谢杂志,2011,27(9):711-717. DOI:10.3760/cma.j.issn.1000-6699.2011.09.003.
[8] International Diabetes Federation(IDF). The IDF consensus worldwide definition of the metabolic syndrome[DB/OL]. http://www.idf.org/webdata/docs/Metac _syndrome_def.Pdf(accessed June 10, 2005).
[9] 黎国德,许庆波,梁岩,等.糖尿病高危人群血脂异常患病率及相关危险因素分析[J].广东医学,2014,35(6):922-924.
[10] 傅媛媛,余金明,王家宏,等.北京社区超重及肥胖人群血脂异常患病及知晓现状[J].中华心血管病杂志,2010,38:562-566. DOI:10.3760/cma.j.issn.0253-3758.2010.06.018.
[11] Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review[J].JAMA,2007,298(7):786-798.
[12] Cai L,Zhang L,Liu A,et al. Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China[J].J Atheroscler Thromb,2012,19(2):159-168.
[13] 陈颖越,金星,蒋兰兰,等.2型糖尿病高尿酸血症患病特点及与代谢综合征关系的分析研究[J].中国糖尿病研究,2012,20:910-912.DOI:10.3969/j.issn.1006-6187.2012.12.008.
[14] Nassar PO, Walker CS, Salvador CS,et al. Lipid profile of people with diabetes mellitus type 2 and periodontal disease[J]. Diabetes Res Clin Pract,2012,96(1):35-39.DOI: 10.1016/j.diabres.2011.11.017.
[15] 吕福平,黄才博,薛耀明.脂质异位沉积与慢性肾脏疾病[J].国际内分泌代谢杂志,2014,34(6):390-392.DOI:10.3760/cma.j.issn.1673-4157.2014.06.008.
[16] De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease[J].Curr Opin Pharmacol,2005,5(2):149-154.
[17] 罗燕堃,李蕴瑶,万蝶云,等.2型糖尿病患者颈动脉内膜中层厚度与血脂的关系[J].中国临床研究,2012,25(2):131-132.
[18] Pereira SS, Alvarez-Leite JI. Low-grade inflammation, obesity, and diabetes[J].Curr Obes Rep,2014,3(4):422-431. DOI: 10.1007/s13679-014-0124-9.

相似文献/References:

[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
　Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(03):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
　Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
　Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(03):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制 ——2014年美国糖尿病协会“杰出科学成就奖” 演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
　Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(03):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
　Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(03):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
　Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(03):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
　Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(03):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
　Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(03):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
　Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(03):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
　Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]

备注/Memo

备注/Memo:
基金项目:天津市科技支撑计划重点项目(13ZCZDSY01300)
更新日期/Last Update: 2016-05-20